Clinical Trials Logo

Recurrent Childhood Rhabdomyosarcoma clinical trials

View clinical trials related to Recurrent Childhood Rhabdomyosarcoma.

Filter by:

NCT ID: NCT03233204 Recruiting - Malignant Glioma Clinical Trials

Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes

Start date: July 24, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body and have come back or do not respond to treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03213704 Recruiting - Malignant Glioma Clinical Trials

Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions

Start date: July 24, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies Trk inhibitor LOXO-101 in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Trk inhibitor LOXO-101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03213678 Recruiting - Malignant Glioma Clinical Trials

Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations

Start date: July 31, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well PI3K/mTOR inhibitor LY3023414 works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body and have come back or do not respond to treatment. PI3K/mTOR inhibitor LY3023414 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03210714 Recruiting - Malignant Glioma Clinical Trials

Pediatric MATCH: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations

Start date: November 6, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03155620 Recruiting - Malignant Glioma Clinical Trials

Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders

Start date: July 24, 2017
Phase: Phase 2
Study type: Interventional

This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

NCT ID: NCT02011126 Withdrawn - Clinical trials for Recurrent Neuroblastoma

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Start date: June 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well imetelstat sodium works in treating younger patients with relapsed or refractory solid tumors. Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01668095 Completed - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

Biomarkers in Patients With Advanced Rhabdomyosarcoma

Start date: August 2012
Phase: N/A
Study type: Observational

This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

NCT ID: NCT01626170 Completed - Clinical trials for Recurrent Childhood Rhabdomyosarcoma

Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma

Start date: June 2012
Phase: N/A
Study type: Observational

This laboratory study is looking into mechanisms of radiation therapy resistance in samples from younger patients with rhabdomyosarcoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer

NCT ID: NCT01614795 Active, not recruiting - Clinical trials for Recurrent Osteosarcoma

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Start date: June 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab and temsirolimus together may kill more tumor cells.

NCT ID: NCT01609803 Completed - Clinical trials for Recurrent Childhood Rhabdomyosarcoma

Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma

Start date: June 2012
Phase: N/A
Study type: Observational

This research trial studies protein expression in tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.